|
|
|
Volumn 13, Issue 4, 2010, Pages 219-223
|
|
HD therapeutics-CHDI fifth annual conference
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACR 16;
ALN HTT;
BIOLOGICAL MARKER;
DOPAMINE RECEPTOR BLOCKING AGENT;
EPI 473;
EPI 743;
HUNTEXIL;
HUNTINGTIN;
LNK 754;
PRIDOPIDINE;
PROTEIN FARNESYLTRANSFERASE INHIBITOR;
SIRTUIN 1;
UNCLASSIFIED DRUG;
ABSENCE OF SIDE EFFECTS;
AMINO TERMINAL SEQUENCE;
CLINICAL TRIAL;
CONFERENCE PAPER;
DISEASE COURSE;
DOPAMINE RECEPTOR BLOCKING;
DRUG EFFICACY;
DRUG SAFETY;
DRUG STRUCTURE;
DRUG SYNTHESIS;
DRUG TARGETING;
DRUG TOLERABILITY;
ELECTROENCEPHALOGRAM;
HUMAN;
HUNTINGTON CHOREA;
LEIGH DISEASE;
NONHUMAN;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PROGNOSIS;
PROTEIN EXPRESSION;
PROTEIN FUNCTION;
ANIMALS;
BIOLOGICAL MARKERS;
DISEASE MODELS, ANIMAL;
DOPAMINE;
DRUG DELIVERY SYSTEMS;
ENZYME INHIBITORS;
FARNESYLTRANSTRANSFERASE;
HUMANS;
HUNTINGTON DISEASE;
LEIGH DISEASE;
LYSOSOMES;
MODELS, BIOLOGICAL;
NERVE TISSUE PROTEINS;
NEURODEGENERATIVE DISEASES;
NUCLEAR PROTEINS;
OLIGONUCLEOTIDES, ANTISENSE;
PHOSPHORYLATION;
PIPERIDINES;
RNA, SMALL INTERFERING;
SHEEP;
SIRTUIN 1;
UBIQUINONE;
|
|
EID: 77950216339
PISSN: 13697056
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (12)
|
|
References (0)
|
